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Systemic  tetrodotoxin  (8  g/kg  SC)  reduced  thermal  hyperalgesia.
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 r  t  i  c  l e  i  n  f  o
rticle history:
eceived 10 July 2015
eceived in revised form
3 September 2015
ccepted 24 September 2015
vailable online 28 September 2015
eywords:
etrodotoxin
hermal injury
hermal hyperalgesia
echanical allodynia
a  b  s  t  r  a  c  t
Burn  injuries  have  been  identiﬁed  as  the  primary  cause  of  injury  in 5%  of  U.S.  military  personnel  evacuated
from  Operations  Iraqi  Freedom  and Enduring  Freedom.  Severe  burn-associated  pain  is  typically  treated
with  opioids  such  as  fentanyl,  morphine,  and  methadone.  Side  effects  of  opioids  include  respiratory
depression,  cardiac  depression,  decrease  in  motor  and  cognitive  function,  as  well  as  the development
of  hyperalgesia,  tolerance  and  dependence.  These  effects  have  led  us  to search  for  novel  analgesics  for
the treatment  of burn-associated  pain  in wounded  combat  service  members.  Tetrodotoxin  (TTX)  is a
selective  voltage-gated  sodium  channel  blocker  currently  in clinical  trials  as an analgesic.  A phase  3
clinical  trial for  cancer-related  pain  has been  completed  and  phase  3 clinical  trials  on chemotherapy-
induced  neuropathic  pain  are planned.  It has  also  been  shown  in mice  to  inhibit  the  development  of
chemotherapy-induced  neuropathic  pain.  TTX  was  originally  identiﬁed  as a  neurotoxin  in  marine  animals
but  has  now  been  shown  to be safe  in  humans  at therapeutic  doses.  The  antinociceptive  effects  of  TTX
are  thought  to be  due  to  inhibition  of Na+ ion  inﬂux  required  for initiation  and conduction  of  nociceptive
impulses. One  TTX  sensitive  sodium  channel,  Nav1.7, has  been  shown  to be essential  in lowering  the
heat  pain threshold  after  burn  injuries.  To date, the  analgesic  effect  of TTX  has  not  been  tested  in burn-
associated  pain.  Male  Sprague-Dawley  rats  were  subjected  to a full  thickness  thermal  injury  on  the  right
hind  paw.  TTX  (8 g/kg)  was  administered  once  a day  systemically  by subcutaneous  injection  beginning
3  days  post  thermal  injury  and  continued  through  7 days  post  thermal  injury.  Thermal  hyperalgesia
and  mechanical  allodynia  were  assessed  60 and  120 min  post  injection  on  each  day  of TTX  treatment.
TTX  signiﬁcantly  reduced  thermal  hyperalgesia  at all days  tested  and  had a less  robust,  but statistically
signiﬁcant  suppressive  effect  on mechanical  allodynia.  These  results  suggest  that systemic  TTX  may  be
an  effective,  rapidly  acting  analgesic  for  battleﬁeld  burn injuries  and  has  the  potential  for  replacing  or
oid  a
evierreducing  the  need  for opi
Published  by  Els
. IntroductionIn 2013 alone, an estimated 450,000 burn incidents were
eported according to the American Burn Association (http://
urninjuryguide.com/burn-statistics/). The severity of burn
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wounds varies, but pain is universal and is especially an issue in
2nd and 3rd degree burns. Burn wounds produce excessive pain
during treatment, which can have a profound impact on the quality
of life and rehabilitation. Our research is focused on improving
pain care for severely burned military service members. Current
management of severe burn pain, both in military and civilian
populations, is primarily through the systemic delivery of opioids,
causing unintended and adverse side effects [2,5]. These include
cardiac and respiratory depression, and decrease in motor and
Y-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. Experimental timeline for thermal injury pain testing. Drug injection daysM.M. Salas et al. / Neurosci
ognition function amongst others. In addition, extended opioid
se is often necessary for the most severely burned patients,
nd can lead to tolerance, opioid-induced hyperalgesia, and
ependence [1,17].
Tetrodotoxin (TTX), a selective voltage-gated sodium (Na+)
hannel blocker, was originally identiﬁed as a neurotoxin in marine
nimals, where it is utilized as a defense against predators [14].
TX has been shown to have analgesic effects in a multitude of
ain models including, the hot-plate test (acute pain model), for-
alin test (persistent pain model), and spinal nerve ligation and
ciatic nerve chronic constriction tests (neuropathic pain models)
16,18,21]. Also, TTX is currently in clinical trials as an analgesic.
 recently completed phase 3 clinical trial for cancer-related pain,
hase 2 clinical trial for chemotherapy-induced neuropathic pain
nd a number of other trials have established overall safety for
umans [10,11]. The antinociceptive effects of TTX are thought to
e due to stabilization of neuronal membranes via inhibition of
a+ ion ﬂux required for initiation and conduction of nociceptive
mpulses. To date, the analgesic effect of TTX has not been tested for
urn pain, although TTX is known to block Na+ channels expressed
n nociceptive ﬁbers [23], including sodium channel Nav 1.7, which
as been shown to be essential in lowering the heat pain threshold
fter burn injury [24].
In this study we have tested the antinociceptive effects of TTX
n a rat hindpaw full thickness thermal injury pain model, which
ecapitulates many aspects of human burn pain [9]. We  show that
TX signiﬁcantly reduces thermal hyperalgesia within 2 h following
dministration and that this effect does not produce hyperalgesia
hen administered daily over several days, as is the case for mor-
hine [15]. Also, TTX did not signiﬁcantly affect motor coordination.
 burn pain indication for TTX would fulﬁll an unmet need for an
nalgesic that can either replace, or reduce quantities of admin-
stered opioid analgesics. These results suggest that TTX could be
eveloped as an effective, rapidly acting analgesic for battleﬁeld
urn injuries.
. Material and methods
.1. Rat full thickness thermal injury (FTTI) model
A total of 27 adult (250–400 g) intact male Sprague-Dawley rats
Charles River Laboratories, Wilmington, MA,  USA) were used in
hese experiments. Rats were pair housed in a 12:12 h light:dark
ycle with ad libitum access to food and water. All studies were
pproved by the U.S. Army Institute of Surgical Research Institu-
ional Animal Care and Use Committee and conformed to the ILAR
uide for the Care and Use of Laboratory Animals and all applicable
ederal, DoD, state, and local regulations. The animal facility is fully
ccredited by AAALAC, Intl.
Rats were subjected to a hindpaw full thickness thermal injury
ain protocol that was developed by our research team [9]. Brieﬂy,
nimals were anesthetized with isoﬂurane and injury was  induced
sing a temperature-controlled super soldering station equipped
ith a slanted soldering tip (RX-80HRT-5.4D; Goot, Hiroshima,
apan). The soldering tip was heated to 100 ◦C and placed on the
ight hindpaw for 30 s, producing an approximately 0.25 m2 ther-
al  injury on the ventral surface of the hindpaw. This procedure
esulted in a partial-thickness thermal injury, which progressed to
ull thickness over the course of 24–48 h. To prevent infection, silver
ulfadiazine (1%) ointment was applied once to the injury..2. Drug treatments
TTX was prepared from proprietary lyophilized product (sup-
lied by WEX  Pharmaceuticals Inc.) under aseptic conditions on(upper row of arrows) as well as thermal and mechanical testing days (lower set of
arrows) are indicated. On days 0,10,14 and 16, when no drugs were administered,
only baseline (BL) measurements were taken.
the day of administration The lyophilized product was reconsti-
tuted with sterile water and further diluted with normal saline to
a ﬁnal concentration of 8 g/ml. Unused portions were stored at
4–8 ◦C for up to 48 h. Vehicle control preparations were made using
identical lyophilized carrier brought to the same ﬁnal volume. Mor-
phine (1 mg/ml) was purchased from Hospira Inc., TTX (8 g/kg),
morphine (5 mg/kg) or vehicle was  administered subcutaneously
(SC) in the ﬂank region at the times indicated in Fig. 1, for systemic
treatment.
2.3. Behavioral testing
Nine rats were treated per group (control/morphine/TTX). All
behavioral tests were performed by observers who were did not
administer the treatments and who were blinded to treatment
allocation. To obtain nociceptive thresholds to an acute noxious
stimulus (hyperalgesia), paw withdrawal latencies (PWL) to a
radiant beam of light were determined utilizing a Paw Thermal
Stimulator (Univ. California, San Diego, CA, USA) as previously
described [13]. Rats were acclimated to the testing apparatuses and
a baseline measurement was taken prior to thermal injury. Drugs
were administered daily for 5 days beginning 72 h post-thermal
injury. PWLs were recorded 60 min  and 120 min  after each drug
administration (Fig. 1). A pretreatment baseline was  also taken
each day immediately prior to drug administration. Nociceptive
responses to a non-noxious mechanical stimulus (mechanical allo-
dynia) were determined using a Dynamic Plantar Aesthesiometer
(Ugo Basile; Collegeville, PA, USA) with automatic detection capa-
bility. For this test, the same rats used for thermal testing were
placed on a mesh grid immediately following the thermal test and
after a 10 min  acclimation period, a blunt probe was  applied to
the plantar surface approximately 5 mm proximal to the thermal
injury. Grams of force applied to elicit withdrawal of the hindpaw
were recorded daily for 5 days beginning 72 h post-thermal injury.
In addition both thermal hyperalgesia and mechanical allodynia
measurements were taken on days 10, 14, and 16 post thermal
injury.
2.4. Data analysis
All data were analyzed using GraphPad Prism software version 5
(GraphPad, San Diego, CA, USA). Pain behavior data are expressed as
mean ± standard error of the mean (SEM) of either PWL  or Force to
Withdrawal. Signiﬁcant outliers were identiﬁed for exclusion with
the Grubbs’ test (GraphPad Quick Calcs Online, the extreme stu-
dentized deviate method; [Z = (mean-value)/standard deviation],
where the value is excluded if Z > 2.21) to detect outliers over 2
standard deviations from the mean. All data were analyzed by
two-way ANOVA and Tukey’s post hoc tests to correct for multiple
comparisons. The statistical signiﬁcance was tested at p < 0.05.
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Fig. 2. (A) Effect of TTX and morphine on thermal hyperalgesia. Paw withdrawal latencies (PWL) to a noxious thermal stimulus were measured daily beginning 3 days post
thermal injury through day 7, on the ipsilateral hindpaw (injured). (B) Effect of TTX and morphine on mechanical allodynia. Force to withdrawal in grams in response to an
innocuous mechanical stimulus, was measured daily beginning 3 days post thermal injury through day 7, on the ipsilateral hindpaw. White, black, and grey bars indicate mean
+/−SEM  for vehicle control, TTX and morphine, respectively. N = 9 for all treatment groups. P values indicate comparisons of each treatment to its respective pretreatment
baseline  (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001), except for the brackets in (A), where the P values are for comparison between TTX and morphine at the 120 min
time  point.
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oig. 3. Long-term effect of prior TTX and morphine administration during recovery
anel)  was  measured as in Figs. 2 and 3, respectively, at the indicated days post-the
o  3,7, and 9 days after the 5th drug treatment. There was no statistically signiﬁcan
. Results
We  used the FTTI burn pain model to determine the effect of TTX
dministration, along with morphine as a positive control, on post-
urn injury pain behaviors in response to both a noxious and non-
oxious stimulus, to determine efﬁcacy for thermal hyperalgesia
nd mechanical allodynia, respectively (Fig. 1).
Statistically signiﬁcant attenuation of thermal hyperalgesia,
easured as increased PWL  compared to baseline (BL) in the ipsilat-
ral hindpaw, was detected at each day of testing for TTX (8 g/kg,
C) and morphine (5 mg/kg, SC) (Fig. 2A). On the ﬁrst day of drug
reatment (Day 3 post-thermal injury) the effect of TTX was not sig-
iﬁcant until 120 min  post treatment, while on the following days
TX had a signiﬁcant attenuation at both 60 and 120 min. Interest-
ngly, a statistically signiﬁcant effect of morphine for attenuation of
hermal hyperalgesia at the 120 min  time point was  only observed
t days 3 and 7, and at each day at this time point the effect of mor-
hine was less than for TTX. The PWL  for TTX and morphine for
he 120 min  time point was statistically signiﬁcantly different for
ays 4, 6 and 7 (Fig. 2A, brackets). We  note that the BL measure-
ents taken on days 4–7 can also be considered 24 h post treatment
easurements for the previous day’s treatments. We  observed no
igniﬁcant effects of either drug on BL values at any time point,
hich is expected for morphine. This indicates that like morphine,
ll of the analgesic effects of TTX are short lived with this dosing
egimen in this model.
TTX attenuated mechanical allodynia to a statistically signiﬁcant
egree, as measured by grams force to withdrawal, at 60 min  post
reatment, at days 3–5, and at 120 min  post treatment at days 5 and
 (Fig. 2B). Morphine attenuated mechanical allodynia at 60 min
ost treatment on all days, and at 120 min  post treatment on days
–7. For both drugs, the attenuating effects on mechanical allodynia
ere less robust than on thermal hyperalgesia.
To assess whether central mechanisms are associated with drug
ffects on behavioral responses, measurements were taken on the
ontralateral (unburned) paw for both for thermal hyperalgesia and
echanical allodynia (Supplementary Fig. 1). Effects of both drugs
n contralateral responses were far less that for the ipsilateral hind-
aw. However some statistically signiﬁcant increases in PWL  were
bserved for each drug the 60 min  post treatment (Supplementary
ig. 1A). An effect on grams force to withdrawal was only observed
or morphine at 120 min  post treatment on day 4 (Supplementary
ig. 1B).
Supplementary material related to this article found, in the
nline version, at http://dx.doi.org/10.1016/j.neulet.2015.09.031. thermal injury. Thermal hyperalgesia (left panel) and mechanical allodynia (right
njury. The same rats were tested as above, such that days 10, 14 and 16 correspond
rence comparing each treatment to vehicle controls at a given time point.
Finally, to assess potential long-term effects of TTX treatment
on pain behaviors, testing was  carried out for the same rats at days
10, 14 and 16 post thermal injury, in the absence of drug treat-
ment. There were no statistically signiﬁcant differences for the rats
previously treated with TTX or morphine when compared to vehi-
cle controls at any time point, for either thermal hyperalgesia or
mechanical allodynia (Fig. 3).
4. Discussion
TTX has been utilized extensively as a tool to study the molec-
ular, biochemical, and pharmacological properties of the 9 Na+
channel isoforms Nav1.1–Nav1.9 [3]. Among these, six are sensi-
tive to nanomolar concentrations of TTX. They are expressed in the
CNS (Nav1.2), in skeletal muscle (Nav1.4), in both the CNS and PNS
(Nav1.1, Nav1.3, and Nav1.6), and in the PNS including sympathetic
neurons (Nav1.7) [7]. The cardiac muscle speciﬁc Nav1.5, as well
as Nav1.8 and Nav1.9, which are both expressed in DRG neurons,
are not sensitive to TTX [25]. The insensitivity of Nav1.5 to TTX
reduces the likelihood of adverse cardiac effects and TTX has not
shown any negative effects in human clinical trials [10,11]. Interest-
ingly Nav1.7 has been shown to contribute to the hyperexcitability
of sensory neurons [6], and more recently investigators used spa-
tially controlled Nav1.7 knock-out mouse models to show that this
channel selectively contributes to neuropathic pain in peripheral
sympathetic neurons [19] and to burn-induced hypersensitivity,
but not mechanical allodynia, in sensory neurons [24].
Accordingly, we set out to test the hypothesis that TTX could
provide analgesia for burn wounds by utilizing a characterized rat
full thickness thermal injury pain model where we measured the
effect of systemic TTX administration on both thermal hyperalgesia
and mechanical allodynia. We  provide evidence from behavioral
assays that TTX is analgesic for thermal injury pain, has a rapid onset
and can have a greater analgesic effect than morphine, particularly
with repeated use over a 5 day time course. TTX had a more robust
suppression of burn-induced thermal hyperalgesia than of mechan-
ical allodynia, which is consistent with the results obtained using
a Nav1.7 knock-out mouse model in which sensory neurons lack
expression [24]. However, we note that those investigators found
no effect of Nav1.7 loss on the development of mechanical allodynia
after burn injury. This would imply that the modest effect that we
observe on suppression of mechanical allodynia is either due to
inhibition of other TTX-sensitive Na+ channels present in the PNS
(Nav1.1, Nav1.3, and Nav1.6), or due to inhibition of Nav1.7 in other
parts of the PNS besides the peripheral nociceptors. Indeed, Minett
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t al. showed that when Nav1.7 was knocked out in all sensory neu-
ons, there was complete loss of all mechanical, inﬂammatory and
eat pain responses [19].
Data collected from the contralateral paw indicated that TTX at
he concentration used (8 g/kg), even when systemically admin-
stered, had minimal observable effect on response behavior. This
ndicates that TTX did not affect the central nervous system in
egards to consciousness or muscle control. This is supported by
revious results showing that TTX did not reduce rotarod latency,
hich is another measure of potential effects of a drug on the
NS and/or muscle function, in a mouse paclitaxel-induced neu-
opathic pain model [20]. In addition, it has long been accepted
hat the majority of TTX effects can be explained through periph-
ral mechanism, and that it does not cross the blood-brain barrier
o signiﬁcant degree [8]. Taken together, along with our data, this
trongly suggests that TTX can provide analgesia through periph-
ral mechanisms of action for cutaneous thermal injury, without
NS and/or muscle function impairment.
Administration of TTX blocked thermal hyperalgesia at each day
f treatment, and by the 2nd day of drug administration (day 4 post
hermal injury), its effect exceeded that of morphine (Fig. 2, left col-
mn). This difference was apparent at 60 min  post-drug treatment,
owever it was statistically signiﬁcant at 120 min  post-drug treat-
ent for days 4, 6, and 7 (Fig. 2A, bracketed asterisks). It is likely
hat repeated morphine injection produced analgesic tolerance in
ur model, as previously reported in multiple opioid studies [22].
mportantly, a tolerance effect, manifested as a reduced effect of
 treatment on the PWL  or grams force to withdrawal, was  not
bserved for TTX. Another concern related to opioid use is the
evelopment of opioid-induced hyperalgesia, which is the para-
oxical increase in sensitivity to painful stimuli experienced after
epeated administration of opioids [4]. Although our experiments
ere not designed to detect this phenomenon, an increase in sen-
itivity to injection was qualitatively observed for the morphine
reated, but not TTX treated rats upon needle stick at time of drug
dministration. This sensitivity, characterized by tensing of muscle,
inching and vocalization at the time of needle stick, was  apparent
y the third or fourth day of injection for only the morphine treated
ats and was most pronounced by the 5th injection.
Finally, in addition to the behavioral testing on days of drug
dministration, both thermal hyperalgesia and mechanical allo-
ynia were tested at days 10, 14, and 16 post thermal injury,
ithout TTX administration. We  observed levels of thermal hyper-
lgesia and mechanical allodynia that are typical for untreated rats
n the FTTI model at those time points; suggesting that there were
o long term effects or likely functional changes to TTX-sensitive
odium channels due to prior daily injections of TTX.
The clinical program for the treatment of cancer related pain
sing TTX has advanced past completion of a phase III trial in Canada
nd Phase III trials for chemotherapy induced neuropathic pain are
lanned in the United States. Through the entire clinical devel-
pment program for the product, TTX has been administered to
ore than 500 patients. The initial phase II study was a multi-dose
fﬁcacy study (ranging from 15 to 90 g TTX daily), followed by a
andomized, double blind, placebo controlled trial using 30 g sub-
utaneous injections b.i.d. for 4 days. The trials showed a reduction
n pain intensity and there was pain relief for up to two weeks
r longer post TTX administration, with only mild motor func-
ion and mild sensory complications reported [10,11]. No loss of
nalgesic effect, signs of addiction, cumulative toxicity, or devel-
pment of tolerance has been reported [12]. Future clinical trials
ill explore other potential applications of TTX. To date, there have
een no clinical trials examining the analgesic effects of TTX for
urn-related pain. Given its efﬁcacy in multiple animal pain mod-
ls, including our ﬁndings in a burn pain model, and the promise
hown in clinical trials for cancer-related pain and chemotherapy
[etters 607 (2015) 108–113
induced neuropathic pain, such trials in a burn indication are war-
ranted.
5. Conclusion
In the present study we  show that TTX is an effective analgesic
in a rat burn wound pain model, and this supports our proposal
to develop TTX as a treatment for burn wound pain. These results
indicate that TTX can produce analgesia that is as effective as,
or superior to morphine, without producing many of the delete-
rious opioid-related side-effects, such as tolerance, hyperalgesia,
or motor function impairment. Our long term goal is to improve
the pain care of US military combat casualties, in particular those
suffering from severe burn wounds. Part of that goal has been to
develop analgesics that can either replace, or reduce the need for
opioids such as morphine and fentanyl, which are currently the
mainstay analgesics for burn pain [2,5]. We  suggest that TTX could
serve as an effective substitute for opioids, both on the battleﬁeld,
as well as at later stages of burn injury care.
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